Laserfiche Joins the Boomi Technology Partner Program, Supporting the Automated, Connected Enterprise
22.2.2023 17:00:00 EET | Business Wire | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced a partnership with Boomi, a leading provider of integration platform as a service known for its speed, ease-of-use, and low total cost of ownership. Through this partnership, organizations can simplify integrations between Laserfiche's robust content services platform and on-premises and cloud applications such as Salesforce, Workday, and Smartsheet using Boomi’s connectors to over 1,500 applications.
“Today’s connected enterprise is built on a robust technology infrastructure, which requires a centralized system to collect and monitor process data, paired with a simplified integration strategy,” said David Everson, Laserfiche’s senior director of strategic solutions. “Laserfiche is excited to bring a proven system for data centralization and process automation to the Boomi ecosystem, enabling more speed, greater agility and stronger security in our customers’ integrations.”
Laserfiche supports organizations in building end-to-end automated solutions that boost productivity, scale with growth and deliver digital-first customer experiences. Laserfiche customers can now take advantage of the enterprise content management (ECM) platform’s Boomi-powered connectors to mission-critical line-of-business applications accelerate integration deployment, more easily manage integration lifecycles and access organization-wide data analytics. The Laserfiche and Boomi partnership is enabling customers to configure and expedite solutions such as:
- Streamlined recruiting and new employee onboarding to move candidates through the hiring process quickly
- Sending/retrieving data to/from popular storage and databases for more flexible data queries and reporting
- Streamlined invoice processing to gain real-time visibility into accounts payable
- Syncing client updates to provide the business with a more holistic view of the client
- Simplified authentication for secure connections to applications
According to The Forrester Wave™: Enterprise iPaaS, Q4 2021, “As more organizations embrace cloud-native, applications and data are more distributed than ever before. Delivering those user experiences and digital business capabilities requires an integration platform that stitches together the ever-growing number of distributed apps and data. Furthermore, the pandemic and quarantines accelerated the need for business process automation and has squeezed IT beyond what it can deliver. In response, organizations are embracing citizen iPaaS as a tool in their business process automation strategy.”
The Boomi Technology Partner Program includes enterprise software companies across applications such as CRM, ERP, HRIS and business intelligence, as well as across industries including government, education, financial services, healthcare and manufacturing. Boomi provides organizations with greater scalability and greater control over data orchestration between application transactions, allowing connectivity to scale as organizations adopt a wider range of solutions.
“We are excited to have Laserfiche as part of our Technology Partnership Program,” said Reggie Penn, global head of technology alliances at Boomi. “A leader in the enterprise content management space, Laserfiche is a solid addition to our profile of partners that offer real solutions that help organizations solve their biggest challenges. The collaboration between Laserfiche and Boomi positions our mutual customers to meet the growing demand for integrations and keep up with the rapid pace of innovation.”
Learn more about the Laserfiche and Boomi partnership by visiting the Laserfiche website.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.
Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare and manufacturing — use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.
Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.
Connect with Laserfiche:
Laserfiche Blog | Twitter | LinkedIn | Facebook
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005010/en/
Contact information
Linda Domingo
Director, Public Relations, Laserfiche
Linda.domingo@laserfiche.com
562-988-1688 ext. 234
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
